HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Caribou Biosciences (NASDAQ:CRBU) and maintained a $24 price target.
May 13, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Caribou Biosciences with a $24 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating and maintenance of a $24 price target by a reputable analyst suggests a strong conviction in the stock's potential. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100